Context: NK3 receptor (“NK3”; TACR3) signaling is implicated in the etiology of hot flashes
by the clinical pharmacology of neurokinin B (NKB) [
[1]
], neuroanatomical evidence for hypertrophy of NKB-expressing neurons in menopausal
women [
- Jayasena C.N.
- et al.
Sci Rep. 2015; 5https://doi.org/10.1038/srep08466
[2]
], and association between risk of vasomotor symptoms and genetic variation in TACR3
[
[3]
]. Fezolinetant is an NK3 antagonist demonstrated to safely modulate hormone biomarkers
in premenopausal women [
- Crandall C.J.
- et al.
Menopause. 2016; https://doi.org/10.1097/GME.0000000000000763
[4]
]. Here, we present clinical trial results for fezolinetant in the treatment of menopausal
hot flashes (“HF”).- Fraser G.L.
- et al.
J Clin Endocrinol Metab. 2016; https://doi.org/10.1210/jc.2015-3621
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to MaturitasAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Sci Rep. 2015; 5https://doi.org/10.1038/srep08466
- Peptides. 2009; 30: 111-122https://doi.org/10.106/j.peptides.2008.05.016
- Menopause. 2016; https://doi.org/10.1097/GME.0000000000000763
- J Clin Endocrinol Metab. 2016; https://doi.org/10.1210/jc.2015-3621
Article info
Identification
Copyright
© 2017 Published by Elsevier Inc.
